27 May 2025 - Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, confirms that the Company’s Annual Report and Accounts for the period ended 31 December 2024 and the notice of Annual General Meeting (“AGM”) will be posted to shareholders today. Read more…
Copenhagen, Denmark – Novo Holdings today announced its financial results for 2024.* Record returns from the Investment Portfolio and growth of the Novo Group companies drive Total Income and Investment Returns to DKK 60 billion (€8.0 billion) for 2024, up from DKK 31 billion (€4.2 billion) in 2023. The Investment Portfolio generated a return of […]
First efficacy data from the clinical trial with HDP-101 in multiple myeloma Expansion of the ADC technology platform to include further payloads New Management Board team Successful financing activities; sales revenue and other income above plan Conference call to be held on 25 March 2024 at 03:00 pm CET/ 10:00 am EDT Ladenburg, Germany, 25 […]
Copenhagen, Denmark – Novo Holdings today announced its financial results for 2022, with a negative -6% return on the Investment Portfolio and Total Income and Returns of DKK 3 billion (€0.4 billion). The positive Total Income and Returns of DKK 3 billion is driven by a strong performance by the Novo Group and resilience in the […]
